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Abstract
Purpose: Studies that analyzed single nucleotide polymorphisms (SNP) in various genes have shown that genetic factors are
strongly associated with age-related macular degeneration (AMD) susceptibility. Copy number variation (CNV) may be an
additional type of genetic variation that contributes to AMD pathogenesis. This study investigated CNV in 4 AMD-relevant
genes in Korean AMD patients and control subjects.
Methods: Four CNV candidate regions located in AMD-relevant genes (VEGFA, ARMS2/HTRA1, CFH and VLDLR), were selected
based on the outcomes of our previous study which elucidated common CNVs in the Asian populations. Real-time PCR
based TaqMan Copy Number Assays were performed on CNV candidates in 273 AMD patients and 257 control subjects.
Results: The predicted copy number (PCN, 0, 1, 2 or 3+) of each region was called using the CopyCaller program. All
candidate genes except ARMS2/HTRA1 showed CNV in at least one individual, in which losses of VEGFA and VLDLR represent
novel findings in the Asian population. When the frequencies of PCN were compared, only the gain in VLDLR showed
significant differences between AMD patients and control subjects (p=0.025). Comparisons of the raw copy values (RCV)
revealed that 3 of 4 candidate genes showed significant differences (2.03 vs. 1.92 for VEGFA, p,0.01; 2.01 vs. 1.97 for CFH,
p,0.01; 1.97 vs. 2.01, p,0.01 for ARMS2/HTRA1).
Conclusion: CNVs located in AMD-relevant genes may be associated with AMD susceptibility. Further investigations
encompassing larger patient cohorts are needed to elucidate the role of CNV in AMD pathogenesis.
Citation: Park JH, Lee S, Yu HG, Kim J-I, Seo J-S (2012) Copy Number Variation of Age-Related Macular Degeneration Relevant Genes in the Korean
Population. PLoS ONE 7(2): e31243. doi:10.1371/journal.pone.0031243
Editor: Anneke I. den Hollander, Radboud University Nijmegen Medical Centre, The Netherlands
Received October 31, 2011; Accepted January 5, 2012; Published February 15, 2012
Copyright:  2012 Park et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant from the Korea Healthcare Technology R&D Project (A080588), Ministry of Health & Welfare, the Republic of Korea.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Jeong-Sun Seo is a PLoS ONE Editorial Board member. Jongil Kim and Jeong-Sun Seo are consulting for Macrogen and Psoma
Therapeutics. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: hgonyu@snu.ac.kr (HGY); jongil@snu.ac.kr (JIK)
. These authors contributed equally to this work.
Introduction
Age-related macular degeneration (AMD) is a major cause of
visual loss in the elderly in industrialized countries, estimated to
affect more than 50 million people worldwide [1,2]. Although the
exact causes of AMD remain obscure, genetic factors are known to
be responsible for AMD development, along with environmental
and ocular factors [2,3].
Genome-wide linkage and association studies have successfully
identified several major chromosomal regions, including 1q31
(CFH) and 10q26 (ARMS2/HTRA1) [4,5]. Along with CFH and
ARMS2/HTRA1, genes associated with inflammation, oxidative
stress, angiogenesis and lipid metabolism have been reported to be
responsible for AMD susceptibility [6,7,8,9].
We have previously discovered common Asian copy number
variations (CNVs) through genotyping 30 individuals from 3 Asian
populations - Korean, Chinese and Japanese. Using microarrays
with 24 million probes, we have discovered 5,177 CNVs, of which
3,547 are putative Asian-specific CNVs [10]. A few studies have
analyzed CNVs of AMD-relevant genes in Caucasians [11,12].
However, the association of the Asian-specific CNVs of these
genes with AMD has not been studied yet.
To verify if the CNVs of AMD-relevant genes are associated
with AMD, we selected candidate CNVs discovered in the Asian
populations and analyzed their status in Korean AMD patients
and control subjects.
Methods
Study population
Consecutive, unrelated AMD patients and control subjects were
recruited from the outpatient clinic at a research hospital from
August 2008 to February 2010. The institutional review board of
the Seoul National University Hospital approved this study, and
written informed consents were obtained from all participants
prior to study entry.
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Related Eye Disease Study (AREDS) grading system by graders
blinded to patient diagnoses [13]. Patients were examined for the
presence of drusen (including appearance and size), pigmentary
abnormalities, geographic atrophy (GA), and choroidal neovascu-
larization. Eyes with only a few small drusen were assigned Grade
1. Eyes with intermediate drusen were assigned Grade 2. Eyes with
large confluent drusen or with pigmentary changes of the retinal
pigment epithelium (RPE) were assigned Grade 3. Eyes with
advanced changes, such as GA or choroidal neovascularization,
were assigned Grade 4. Eyes with none of the above were assigned
Grade 0. Patients were graded based on the worse eye. When
choroidal neovascularization was suspected, fluorescein angiogra-
phy was performed to confirm its presence. Subjects with Grade 0
were enrolled as controls. Because patients with a few small drusen
have nominal AMD risk [13], subjects with Grade 1 were
excluded from the AMD group. Only subjects older than 50 years
were included in this study. In total, 273 AMD patients and 257
control subjects were enrolled. Information obtained included
relevant past medical history, smoking history, and ocular history.
Height, weight and body mass index (BMI) measurements were
also recorded.
DNA extraction and quantification
Ten milliliter (10 mL) of peripheral blood sample was collected
from each study subject, and centrifuged for 5 min at 2000 g to
separate the serum. DNA was extracted using FlexiGene DNA kit
(Qiagen. Inc, Hilden, Germany) according to the manufacturer’s
protocol and stored at 270uC. DNA concentrations were
measured by Nanodrop ND-1000 spectrophotometer (Nano-drop
Technologies, Wilmington, DE). Samples from AMD patients and
control subjects were collected during the same period and
processed using the same method.
Selection of target regions and copy number
determination
Among CNVs discovered previously in the Asian populations,
we selected candidate CNVs that overlapped with genes currently
suspected to play crucial roles in AMD pathogenesis. The number
of candidate CNVs was narrowed down to 4, each located in
VEGFA, ARMS2/HTRA1, CFH and VLDLR (Tables 1 and S1).
We performed real-time PCR to determine CNV status on each
sample. TaqMan probes, which were designed by the manufac-
turer (Applied Biosystems, Foster City, CA), were used to target
the specific regions. RNase P (Taqman Copy Number Reference
Assay, Applied Biosystems, Foster City, CA) was chosen as a
reference gene, of which every human is known to possess 2
copies. Every reaction was duplicated in 384 well plates, and each
plate was comprised of almost an equal number of disease and
control samples. Real-time PCR was performed using the Applied
Biosystems 7900HT Fast System and Sequence Detection Systems
Software v2.3. The thermal cycling condition was as follows:
holding at 95uC for 10 min, 40 cycles for 15 s at 95uC for
denaturation and 60 s at 60uC for amplification.
Applied Biosystems CopyCaller
TM Software v1.0 was used to
determine the copy number status of each target region, and
calculation was performed according to a maximum-likelihood
algorithm of the software. Raw copy value (RCV) represents a
non-integer number of copy calculated, whereas predicted copy
number (PCN) is defined as an integer number of copy determined
by the algorithm (0, 1, 2, or 3+). Copy number (CN) gain is
defined as PCN higher than 2, and PCN lower than 2 would be
regarded as CN loss.
Statistical method for analysis
We performed a two-tailed t-test to evaluate the difference in
mean values of RCV between the disease and control groups. A
chi-square test was used to compare the frequency of CN gain and
loss respectively between the two groups. For both analyses,
statistical significance was deemed to have been reached when the
p-value was lower than 0.05 (p,0.05).
Results
The clinical characteristics of AMD patients and control
subjects are summarized in Table 2. Among 273 AMD patients,
neovascular AMD was diagnosed in 126 and non-neovascular
AMD in 147 patients. Seventy-six patients had AMD of grade 2,
67 patients had AMD of grade 3 and 130 patients had AMD of
grade 4, The mean age and gender distributions were not
significantly different between the AMD and control groups.
There was no significant difference in BMI between the two
groups.
We attempted to predict the integer value of CN (PCN) at
each region and the results were summarized in Table 3. All
candidate regions except ARMS2/HTRA1 showed either CN
gain or loss. CN gains in VEGFA and VLDLR genes had been
reported in the previous study on 30 Asian samples. However,
CN losses in VEGFA and VLDLR genes, which were detected in 3
Table 1. Target CNVs on causative genes.
Affected Gene Mapped ID CNV start CNV end Gain Suspected/Loss Suspected Among 30 Individuals
VEGFA NM_001025369 43845963 43846991 1 (JPT 1)/0
ARMS2/HTRA1 NM_002775 124183770 124255215 1 (JPT 1)/0
CFH NM_000186 194975094 195095411 0/5 (CHB 3, JPT 2*)
VLDLR NM_003383 2610547 2613694 1 (CHB 1)/0
*CHB: Han Chinese from Beijing, JPT: Japanese from Tokyo.
doi:10.1371/journal.pone.0031243.t001
Table 2. Patient demographic characteristics.
AMD (n=273) Control (n=257) p-value
Sex (M/F) 130/143 105/152 0.38
Age (yr) 67.367.9 67.668.5 0.24
Body Mass Index (kg/m
2) 24.0463.15 24.2063.27 0.64
doi:10.1371/journal.pone.0031243.t002
CNVs in Age-Related Macular Degeneration
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31243and 29 subjects respectively, were novel findings in the Asian
population.
In AMD patients, CN loss of VEGFA gene was not detected and
one CN gain was found. The patient with CN gain of VEGFA gene
had neovascular AMD in the left eye and intermediate AMD in
the right eye (Figure 1A). Three subjects in the control group
showed CN losses in VEGFA, whereas no CN gain was detected.
No AMD patient or control subject presented with CN gain at
CFH, and only 1 AMD patient presented with CN loss. The
patient with CN loss at CFH had intermediate AMD with
confluent drusen in both eyes (Figure 1B). CN gain and loss in
VLDLR gene were more common compared to other regions,
contributing more than one third of total subjects. The number of
CN gain in VLDLR gene was much higher in control subjects than
in AMD patients (p=0.025), while CN loss was not significantly
different between the patient and control groups.
To overcome false negative calls that could be generated in the
process of CN prediction, we also analyzed the mean RCV which
was not a whole number. When the mean RCV of each region
was analyzed between the patient and control groups, patients
with AMD had significantly higher RCV than controls at VEGFA
and CFH (2.03 vs. 1.92 for VEGFA, p,0.01, 2.01 vs. 1.97 for CFH,
p,0.01), and lower RCV at ARMS2/HTRA1 (1.97 vs. 2.01,
p,0.01, Table 4).
Discussion
Recent studies have suggested that CNVs play important roles
in the development of inheritable diseases [14]. Although less
abundant than SNP, CNV seems to account for more nucleotide
variation due to its sheer size [15]. By spanning thousands of bases,
CNVs often encompass functional DNA sequences. A recent
comparison of the relative impact of SNP and CNV on gene
expression identified that a substantial proportion (,18%) of gene
expression variability might be attributable to known CNVs [15].
In this study, we found three out of four candidate regions
showed CNVs in AMD patients or control subjects. CNV
frequencies in some regions were found to differ from those of
our previous screening study. For instance, we previously found
Table 3. Association between AMD cases and controls.
AMD Control p-value
VEGFA
Gain 1 0 0.33
Normal 272 254
Loss 0 3 0.074
ARMS2/HTRA1
Gain 0 0 n/a
Normal 273 257
Loss 0 0 n/a
CFH
Gain 0 0 n/a
Normal 265 253
Loss 1 0 0.33
VLDLR
Gain 63 82 0.025
Normal 184 142
Loss 20 29 0.12
doi:10.1371/journal.pone.0031243.t003
Figure 1. Fundus photographs in patients with copy number (CN) gain or loss. A 78-year-old man with CN gain at VEGFA showed typical
features of neovascular AMD; with choroidal neovascularization in the left eye and confluent drusen in the right eye (A). Fluorescein angiography and
spectral domain optical coherence tomography (SD-OCT) show choroidal neovascularization with cystoid macular edema at the center of the
choroidal neovascularization in the left eye. The patient with CN loss at CFH gene was a 66-year-old woman with confluent soft drusen in both eyes
(B). Flourescein angiography shows multiple hyper-fluorescent lesions at macula of both eyes and SD-OCT shows clumps in the neurosensory retina
and focal elevations of retinal pigment epithelial layer.
doi:10.1371/journal.pone.0031243.g001
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none of the AMD patients and control subjects demonstrated CN
loss at this site. Ethnic differences may be responsible for this
discrepancy. In case of CFH loss, every CNV loss was discovered
in the Chinese and Japanese, yet not in Koreans. The detection
of CNV could be platform-dependent as well. A previous study
discovered CNVs using array CGH, whereas this study used
TaqMan probes based on real-time PCR. Furthermore, we used
the CopyCaller program and maximum-likelihood algorithm to
determine CN or predicted CN, and set the most frequent CN at
2. However, if there is a region with more than 2 copies in the
actual human genome, its CN determination would have a
number of false results. Regions with high frequencies of CNV,
such as VLDLR in our study, could be suspected as multi-copy
loci.
Considering factors mentioned above, the issue of false CNV
may be the first hurdle to overcome for this kind of association
study. In addition to the duplication of experiments, we repeated
experiments for samples with CN gain and loss to avoid false
positive CNV calls, and confirmed whether they were consistent
with previous experiments. CN gain or loss of VLDLR, however,
was excluded from these re-experiments, since this region
appeared to be highly CNV-prone in both patient and control
groups. CN gains and losses of other three regions shown in
Table 4 were all confirmed by two separate experiments. Besides,
all the plates were designed as almost an equal number of patient
and control samples since false calls might occur randomly in each
plate.
PCN would be the most apparent and decisive value showing
the CNV status of each individual if RCV is converted well into
PCN without error. However, we found several cases showing
borderline RCVs, which make it difficult to determine whether
they have two copies or not. To overcome these kinds of false
negative or positive calls, we also compared the mean RCV
between patient and control groups and showed the possible
association of candidate genes with the AMD development.
Vascular endothelial growth factor (VEGF) is a major
molecular mediator of neovascularization. Intraocular VEGF
expression was found to be increased in neovascular AMD
patients, which led to the development of VEGF inhibition
therapies with anti-VEGF antibodies for neovascular AMD [16].
However, studies analyzing SNP did not show consistent results
[9,17]. In this study, CN loss in VEGFA was discovered in 3
control subjects, which had not been reported in the Asian or
Caucasian populations before. Although our study analyzed a
relatively large number of AMD patients and controls, further
investigations should be conducted in other ethnic groups to
confirm the possible effects of CNV on VEGFA gene in AMD
development. In addition, because the CNV in VEGFA gene
appeared to be rare in the Korean population, larger sample sizes
are required for further studies.
The ARMS2/HTRA1 gene encodes a member of a family of
serine proteases expressed in both mouse and human retinas,
and its expression in human fibroblasts increases with aging [18].
Over-expression of ARMS2/HTRA1 alters the integrity of the
Bruch’s membrane, favoring the invasion of choroid capillaries
across the extracellular matrix, as occurs in wet AMD [19]. In
this study, on the contrary, the mean RCV at ARMS2/HTRA1
was lower in AMD patients compared to control subjects. Since
there was no CN gain or loss predicted, studies to elucidate the
genuine CNV status of ARMS2/HTRA1 in AMD patients, and
its possible effect on ARMS2/HTRA1 expression would be
needed.
Genes encoding complement factors have been identified as
AMD susceptibility loci with convincing statistical evidence. They
include complement factor H gene (CFH) on chromosome 1q32
[20], complement component 3 gene on 19p13 [21], and 2
neighboring genes on 6p21 (complement factor B and comple-
ment component 2) [17,19]. This study discovered CN loss of
CFH gene in one AMD patient but it could not find any
association of CFH variation with AMD. Other complement
factor genes and complement factor related regions may find
significant genetic variations in complement factor related genes
in AMD patients.
Very low density lipoprotein receptor (VLDLR) is involved in
lipid transportation and chronic inflammation through the Wnt
pathway [22,23]. VLDLR gene knockout (VLDLR2/2) mice were
shown to develop sub-retinal neovascularization [24,25] and the
features of neovascularization resemble those of retinal angioma-
tous proliferation in human — a subtype of AMD [17]. In an
association study, variations (rs10967213, rs2290465) of VLDLR
showed associations with AMD prevalence [26,27]. In this study,
the CN gain or loss of VLDLR was very common in control
subjects and in AMD patients. It may be due to its regional
complexity in the human genome, and therefore this region should
be interpreted with caution.
In this study, we selected target CNVs out of Asian-specific
CNVs discovered in our previous study. Consequently, several
genes which have been thought to play important roles in AMD
pathogenesis and widely studied in other ethnic groups, such as
C2/BF, TIMP, CFHR1 and CFHR3, were not included in our
target regions.
In conclusion, the outcome of this study suggests that some
CNVs might be associated with AMD development, although the
actual action of these CNVs in vivo remains unelucidated. Further
CNV-oriented research is required to improve our understanding
of the mechanism that underlies AMD.
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Table 4. Mean copy number in AMD cases and controls.
Genes AMD Control p-value
VEGFA 2.03 1.92 ,0.01
ARMS2/HTRA1 1.97 2.01 ,0.01
CFH 2.01 1.97 ,0.01
VLDLR 2.14 2.22 0.176
doi:10.1371/journal.pone.0031243.t004
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